US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by NeuroPace, Inc.

News headline image
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Present at the Leerink Global Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace to Participate in Upcoming Healthcare Conferences
From NeuroPace, Inc.
Via Business Wire
Tickers NPCE
News headline image
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE
News headline image
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
Tickers NPCE